Results Roundup: Commitment Undimmed By Mixed Emerging Markets
This article was originally published in PharmAsia News
The last quarter provided a decidedly varied set of results for multinational pharma firms active in Asian and other developing markets, with some adjusting to shifting conditions in leading market China better than others, while pricing pressures and rising competition took a toll on some. Meanwhile at major Indian firms, acquisitions were both helping and hampering the performance of top companies.
Register for our free email digests: